Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
NCT: NCT06830265 · RECRUITING
Brief Summary
Prostate biopsy is the definitive examination to establish the diagnosis of prostate cancer, but up to 40% of these biopsies overestimate or underestimate the severity of the disease. A novel biopsy needle system captures substantially more tissue than standard of care needles, but it is important to assess the retrieval of tissue for pathologic analyses. This study will compare quality and quantity of tissue retrieved by both systems. Further, tissue will be analyzed using computational pathology algorithms for atypical small acinar proliferation and Gleason scores in terms of tissue area, tissue length, and tissue tortuosity.
Frequently Asked Questions
What is Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis?
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis is a clinical trial registered under NCT06830265. Current status: RECRUITING.
What is the status of NCT06830265?
The current status of NCT06830265 (Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis) is: RECRUITING.
When did Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis start?
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis started on 2025-07-07.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.